XML 42 R145.htm IDEA: XBRL DOCUMENT v2.4.0.6
Schedule II - Condensed Financial Information of Registrant (Statement of Income and Comprehensive Income) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Jun. 30, 2010
XLIT Ltd.
Dec. 31, 2010
Xl Group PLC
Dec. 31, 2012
Xl Group PLC
Dec. 31, 2011
Xl Group PLC
Condensed Financial Statements Captions [Line Items]                              
Net investment income                 $ 1,012,348 $ 1,137,769 $ 1,198,038 $ 44,636 [1] $ 0 $ 5 $ 2
Realized investment gains (losses):                              
Net realized gains (losses) on investments sold                 94,810 (28,187) (65,670) 25,177 [1] 0 0 0
Other-than-temporary impairments on investments                 (54,306) (174,102) (170,643) (11,670) [1] 0 0 0
Other-than-temporary impairments on investments transferred to (from) other comprehensive income                 (26,406) 13,930 (34,490) 4 [1] 0 0 0
Net realized gains (losses) on investments                 14,098 (188,359) (270,803) 13,511 [1] 0 0 0
Net realized and unrealized (gains) losses on derivative instruments                 5,221 (10,738) (33,843) (4,087) [1] 0 0 0
Equity in net earnings of subsidiaries                       384,311 [1] 275,629 662,280 (400,612)
Equity in net income (loss) in operating affiliates                 114,314 103,039 172,474 2 [1] 0 0 0
Total revenues                 7,230,480 6,696,803 6,398,582 438,373 [1] 275,629 662,285 (400,610)
Operating expenses                 1,173,951 1,083,917 972,963 48,256 [1] 9,930 10,971 74,422
Exchange gains (losses)                 10,546 (40,640) (10,161) 1,003 [1] 34 165 (275)
Interest expense                 172,205 205,592 213,643 51,431 [1] 0 15 3
Total expenses                 6,521,874 7,117,765 5,713,836 100,690 [1] 9,964 11,151 74,150
Income loss before tax                       337,683 [1] 265,665 651,134 (474,760)
Provision (benefit) for income tax                 34,028 59,707 162,737 (202) [1] 0 0 0
Net income (loss) attributable to XL Group plc                 651,134 (474,760) 603,550 337,885 [1] 265,665 651,134 (474,760)
Dividends on Series C and Series E preference ordinary shares                 0 0 (34,694) (34,694) [1] 0 0 0
Gain on redemption of Redeemable Series C preference ordinary shares                 0 0 16,616 16,616 [1] 0 0 0
Net income (loss) attributable to ordinary shareholders 81,448 171,902 221,156 176,628 (515,537) 42,398 225,663 (227,284) 651,134 (474,760) 585,472 319,807 [1] 265,665 651,134 (474,760)
Impact of adoption of new authoritative embedded derivative guidance, net of taxes                 0 0 31,917 0 [1] 31,917 0 0
Change in net unrealized gains (losses) on investments, net of tax                 992,891 332,720 932,769 880,332 [1] 161,048 887,376 471,696
Change in OTTI losses recognized in other comprehensive income, net of tax                 67,280 39,456 124,906 31,637 [1] 93,269 67,280 39,456
Change in underfunded pension liability                 (9,985) (2,622) (2,619) (3,567) [1] 6,186 9,985 2,622
Change in value of cash flow hedge                 439 439 439 (220) [1] (219) (439) (439)
Change in net unrealized gain (loss) on future policy benefit reserves                 0 0 (3,714) (3,714) [1] 0 0 0
Foreign currency translation adjustments                 (8,163) (26,700) 50,953 (108,308) [1] 159,261 (8,163) (26,700)
Comprehensive income (loss)                 1,588,081 7,509 1,846,812 1,141,619 [1] 705,193 1,588,081 7,509
Parenthetical information, dividends:                              
Dividends received from subsidiaries                       $ 197,326 $ 448,400 $ 0 $ 183,029
[1] As part of the Redomestication on July 1, 2010, XL-Cayman became a wholly-owned subsidiary of XL-Ireland, and as such, certain of the above financial data with respect to periods prior to the Redomestication are not comparable for periods subsequent to the Redomestication.